A dual strategy - and - to evaluate human antitetanus mAbs addressing their potential protective action on TeNT endocytosis in primary rat neuronal cells

Cauã Pacheco Lima,Gabriela Massaro Barreiros,Adriele Silva Alves Oliveira,Marcelo Medina Souza,Tania Maria Manieri,Ana Maria Moro

DOI: https://doi.org/10.1101/2024.02.25.582016

2024-02-28

Abstract:Tetanus disease is caused by the spore-forming bacteria Clostridium tetani. Its development starts with wounds or mucous layers of spore contact in water, soil, human, and animal feces. It is prevented by vaccination, but the lack of booster shots throughout life and age-decreased immune surveillance by immunosenescence enforces prophylactic treatment in case of accidents. The disease incident and lethality present a high index in underdeveloped countries. In cases of infection, administering antitetanus antibodies is preconized, usually derived from immunized horses or humans. Heterologous sera origin and the total protein content represent risks such as serum sickness and serum sickness-like reactions. Human sera can carry unknown viruses. The search for human monoclonal antibodies (mAbs) against TeNT (tetanus toxin) has increased in the last few years, although none has been approved. From a panel of previously identified human mAbs derived from B-cell sorting, we selected two nonrelated mAbs that bind to HCR/T (fragment C) of TeNT, showing disruption of its interaction with the cellular receptor ganglioside GT1b. To gain more insight into the TeNT inhibition effectiveness, we present results based on cellular assays and molecular docking tools. We describe TeNT internalization in neurons derived from the neonatal rat spinal cord. Adding the single mAbs prevented TeNT internalization higher than 50% under a specific experimental condition. The data validation was performed by quantitative analysis of immunofluorescence punctate staining of Alexa Fluor 647 conjugated to TeNT. We also confirmed the Synaptic Vesicle Glycoprotein (SV2) mediator role in TeNT endocytosis. The molecular docking assays to predict potential TeNT epitopes of the mAbs showed the binding of both antibodies to the heavy chain of TeNT, specifically to the HCR/T domain. A higher incidence was found between N1153 and W1289 when evaluating candidate residues for conformational epitope.

Immunology

What problem does this paper attempt to address?

The paper aims to address the following key issues:

1. **Evaluate the impact of human monoclonal antibodies (mAbs) on the endocytosis of tetanus toxin (TeNT)**: The study investigated the effects of two unrelated anti-tetanus human monoclonal antibodies (TT-117 and TT-140) on the interaction between TeNT and neuronal cells in in vitro cell experiments. Both antibodies were able to bind to the heavy chain region (HCR/T) of TeNT and could inhibit the binding of TeNT to its cell surface receptors, such as ganglioside GT1b.

2. **Explore how antibodies prevent TeNT from entering neuronal cells**: Cell experiments were conducted to verify whether these two antibodies could effectively reduce the endocytosis of TeNT in rat spinal cord neuronal cells, and further analyzed how the antibodies affect the interaction between TeNT and synaptic vesicle glycoprotein II (SV2).

3. **Molecular docking study**: Molecular docking tools were used to predict the potential binding sites between these antibodies and TeNT, to understand how the antibodies block the binding of TeNT to cell surface receptors by binding to the HCR/T region of TeNT.

4. **Validate antibody binding sites**: By analyzing the results of molecular docking, the binding sites of the two antibodies to TeNT were identified, and these sites were located in the HCR/T domain but did not directly cover the key residues that bind to GT1b. This suggests that the antibodies may prevent TeNT from binding to cell surface receptors by altering the conformation of TeNT or creating spatial hindrance.

In summary, this study evaluated the inhibitory effects and mechanisms of two human monoclonal antibodies on the endocytosis of tetanus toxin through cell biology experiments and molecular simulation methods, providing experimental evidence for the development of new anti-tetanus therapies.